Abstract
Prediction of tautomers plays an essential role in computer-aided drug discovery. However, it remains a challenging task nowadays to accurately predict the canonical tautomeric form of a given drug-like molecule. Lack of extensive tautomer databases, most likely due to the difficulty in experimental studies, hampers the development of effective empirical methods for tautomer predictions. A more accurate estimation of the stable tautomeric form can be achieved by quantum chemistry calculations. Yet, the computational cost required prevents quantum chemistry calculation as a standard tool for tautomer prediction in computer-aided drug discovery. In this paper we propose a hybrid quantum chemistry-quantum computation workflow to efficiently predict the dominant tautomeric form. Specifically, we select active-space molecular orbitals based on quantum chemistry methods. Then we utilize efficient encoding methods to map the Hamiltonian onto quantum devices to reduce the qubit resources and circuit depth. Finally, variational quantum eigensolver (VQE) algorithms are employed for ground state estimation where hardware-efficient ansatz circuits are used. To demonstrate the applicability of our methodology, we perform experiments on two tautomeric systems: acetone and Edaravone, each having 52 and 150 spin-orbitals in the STO-3G basis set, respectively. Our numerical results show that their tautomeric state prediction agrees with the CCSD benchmarks. Moreover, the required quantum resources are efficient: in the example of Edaravone, we could achieve chemical accuracy with only eight qubits and 80 two-qubit gates.
Introduction
In the realm of drug discovery, molecules often exist as tautomers—isomers that rapidly interconvert by relocating a proton and shifting double bonds. Identifying the dominant tautomeric form is vital for predicting how a drug interacts with biological targets. However, experimental data is scarce, and classical computational methods face an "exponential wall" as molecular complexity increases. This study introduces a hybrid quantum-classical workflow designed to overcome these limitations using the Variational Quantum Eigensolver (VQE) on near-term quantum hardware.
Methodology
The researchers developed a six-step hybrid workflow to bridge classical preprocessing with quantum execution:
- Geometry Optimization: Classical Density Functional Theory (DFT) at the B3LYP level determines the 3D structure.
- Orbital Construction: MP2 methods build the molecular orbital space.
- Active Space Selection: Identifying the "active" electrons and orbitals most critical to the chemical transition to fit current hardware constraints.
- Qubit-Efficient Encoding (QEE): A mapping technique that exploits symmetries to represent the Hamiltonian logarithmically, significantly reducing qubit requirements compared to standard Jordan-Wigner mappings.
- Variational Quantum Eigensolver (VQE): A feedback loop where a quantum device estimates energy and a classical optimizer updates parameters to find the ground state.
- Hardware-Efficient Ansatz: Staggered entangling layers optimized for Noisy Intermediate-Scale Quantum (NISQ) devices.
Case Studies and Results
Acetone: Proof of Concept
Acetone serves as a simple keto-enol system to validate the workflow. The study analyzed the electrostatic potential maps and molecular orbital energies (HOMO/LUMO) to ensure the quantum simulation aligned with known chemical properties.
Edaravone: Pharmaceutical Application
Edaravone, an FDA-approved drug for ALS, presents a more complex challenge with three tautomeric forms (keto, enol, and amine) and 150 spin-orbitals. Using QEE, the problem was compressed from a potential 150 qubits down to just 8 qubits.
The workflow achieved chemical accuracy (error < 1 kcal/mol) for Edaravone using only 80 CNOT gates. The predicted stability order of the tautomers matched high-level classical CCSD (Coupled Cluster Singles and Doubles) benchmarks.
Discussion
A key finding was the effectiveness of the QEE method in reducing the "quantum footprint." By focusing on physically relevant electronic configurations, the researchers demonstrated that meaningful pharmaceutical simulations are possible on NISQ-era devices. Furthermore, initializing VQE with a Gaussian distribution of parameters helped mitigate "barren plateaus," a common optimization hurdle in quantum computing.
Conclusion and Future Work
While successful, the current model operates "in vacuo." Future iterations aim to include Continuum Solvation Models to account for the significant impact of water and pH on tautomer stability in biological systems. Additionally, automating active space selection and testing on physical quantum processors remain critical steps toward integrating quantum computing into the standard drug discovery pipeline.
Summary updated